![]() ![]() ![]() These patients are successfully rendered disease-free following treatment with current standards of care, and then are sent home to watch and wait with the hope their cancer never returns. "Approximately fifty percent of breast cancer patients have tumors that are HER2 1+ or 2+. (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments, today announced the initiation of its Phase 3 PRESENT trial for NeuVax TM (E75 peptide plus GM-CSF) vaccine in HER2 1+ and 2+ breast cancer patients (often referred to as HER2 negative) in the adjuvant setting to prevent recurrence. 20, 2012 (GLOBE NEWSWIRE) - Galena Biopharma, Inc. Phase 3 trial being conducted under FDA-approved Special Protocol Assessment initiated ahead of schedule.NeuVax adjuvant therapy intended for patients not eligible for Herceptin® (trastuzumab) therapy.Galena Biopharma Initiates Patient Enrollment in NeuVax(TM) Phase 3 PRESENT Trial to Prevent Breast Cancer Recurrence ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |